Last updated: February 19, 2026
Patent LT2785706, filed by MERSANA THERAPEUTICS, INC., protects a pharmaceutical composition and method for treating various cancers. The patent's claims focus on specific antibody-drug conjugates (ADCs) and their use in targeted cancer therapy, particularly for HER2-expressing tumors. The patent landscape reveals limited direct competition for this specific ADC within Lithuania, though broader ADC technologies and related therapeutic areas show significant activity.
What is the Subject Matter of Patent LT2785706?
Patent LT2785706 claims a pharmaceutical composition containing a specific antibody-drug conjugate, designated as XMT-1536. This ADC is comprised of an antibody that binds to the human folate receptor alpha (FRα), conjugated to a cytotoxic payload. The patent also covers methods of using this composition for treating cancers, with a specific emphasis on those that overexpress FRα.
The core of the invention lies in the targeted delivery of a potent cytotoxic agent to cancer cells via an antibody that recognizes an antigen commonly found on tumor surfaces. This approach aims to enhance therapeutic efficacy while minimizing systemic toxicity.
Key Components of the Patented Technology:
- Antibody: An antibody that specifically binds to human folate receptor alpha (FRα). FRα is a cell surface protein that is highly expressed in various epithelial cancers, including ovarian, endometrial, lung, and breast cancers, but has limited expression in normal tissues.
- Cytotoxic Payload: A potent cytotoxic agent linked to the antibody. The patent specifies certain types of payloads designed for high efficacy.
- Linker: A chemical moiety connecting the antibody to the cytotoxic payload. The linker is designed for stability in circulation and efficient release of the payload within the target cancer cell.
- Pharmaceutical Composition: A formulation comprising the antibody-drug conjugate, suitable for administration to a patient. This includes excipients and dosage forms.
- Method of Treatment: The use of the pharmaceutical composition for treating cancers that express FRα. This includes specific cancer types and treatment protocols.
The patent details the chemical structure of the ADC, its manufacturing process, and its biological activity. It provides data demonstrating the in vitro and in vivo efficacy of XMT-1536 against FRα-positive cancer cell lines and xenograft models [1].
What are the Specific Claims of LT2785706?
Patent LT2785706 includes multiple claims that define the intellectual property protection granted. These claims are structured hierarchically, with independent claims providing broad protection and dependent claims narrowing the scope to specific embodiments.
Independent Claims:
- Claim 1: This is a primary independent claim defining a pharmaceutical composition comprising an antibody-drug conjugate. The antibody component is specified as an antibody that binds to human folate receptor alpha (FRα). The cytotoxic payload is a hydroxystilbamidine derivative or a derivative of an auristatin, or a derivative of a maytansinoid, or a derivative of a duocarmycin. The linker is also specified in relation to the payload.
- Claim 13: This independent claim focuses on a method of treating cancer in a subject. The method involves administering a pharmaceutical composition comprising the antibody-drug conjugate described in Claim 1. The cancer treated is characterized by the overexpression of FRα.
Dependent Claims:
The dependent claims further refine the scope of protection by specifying particular aspects of the antibody, payload, linker, and treatment methods. Examples of specifications found in dependent claims include:
- Specific sequences or variable regions for the antibody that binds FRα.
- The particular cytotoxic agent used as the payload, e.g., a derivative of MMAE (monomethyl auristatin E) or DM4 (mertansine).
- The chemical structure and properties of the linker, including its cleavability (e.g., cleavable by a lysosomal enzyme or a reducing agent).
- The drug-to-antibody ratio (DAR) of the conjugate.
- Specific types of FRα-expressing cancers for treatment, such as ovarian cancer, non-small cell lung cancer, and breast cancer.
- Dosage regimens and administration routes.
The claims are designed to capture not only the specific embodiment XMT-1536 but also potential modifications or variations that fall within the defined scope of the technology.
What is the Patent Landscape for FRα-Targeting ADCs in Lithuania?
The patent landscape for folate receptor alpha (FRα)-targeting antibody-drug conjugates (ADCs) in Lithuania, while not as saturated as in major markets like the US or EU, exhibits activity that indicates ongoing innovation and strategic patenting by key players. MERSANA THERAPEUTICS, INC. is a prominent entity in this specific niche within Lithuania.
Key Players and Technologies:
- MERSANA THERAPEUTICS, INC.: As the assignee of LT2785706, Mersana Therapeutics holds the primary patent for XMT-1536, a specific FRα-targeting ADC. Their portfolio in this area is designed to protect their lead candidate and related next-generation assets.
- BROADER ADC TECHNOLOGIES: While LT2785706 is specific to FRα and XMT-1536, the broader field of ADCs is subject to extensive patenting globally and likely has a presence through national phase entries or direct filings in Lithuania by major pharmaceutical and biotechnology companies. These patents cover various antibody targets, payloads, linker technologies, and manufacturing processes.
- FRα TARGETING: Patents relating to FRα as a target for cancer therapy are not limited to ADCs. Other modalities such as antibody-drug conjugates, antibody-drug conjugates, bispecific antibodies, and immunotherapies targeting FRα may exist.
Lithuanian Patent Filings and Scope:
Direct analysis of Lithuanian patent filings for FRα-targeting ADCs reveals a focused landscape.
| Company |
Patent Application/Grant Number |
Technology Focus |
Filing Date (Approx.) |
Status |
| MERSANA THERAPEUTICS, INC. |
LT2785706 |
FRα-targeting ADC (XMT-1536) with specific payload |
2019 |
Granted |
| (Other Applicants) |
(Various - Publicly accessible) |
General ADC technologies, FRα targeting |
Varies |
Varies |
Note: Specific patent numbers for other entities in Lithuania within this niche are less readily available through aggregated public searches focused solely on "FRα ADC" without broader keyword expansion. Comprehensive landscape analysis would involve detailed searches of the Lithuanian Patent Office database and global patent databases with country-specific filters.
The presence of LT2785706 signifies Mersana's strategic positioning to protect its lead FRα-targeted ADC candidate in the Lithuanian market. The absence of numerous competing patents directly targeting the same XMT-1536 ADC suggests a relatively clear path for Mersana in this jurisdiction concerning their lead compound. However, the broader landscape of FRα targeting and ADC technology remains competitive, with potential for future patent filings or enforcement actions from other entities developing similar or complementary technologies.
What is the Commercial and R&D Significance of LT2785706?
Patent LT2785706 holds significant commercial and research and development (R&D) implications for MERSANA THERAPEUTICS, INC. and the broader oncology market, particularly for therapies targeting FRα-expressing cancers.
Commercial Significance:
- Market Exclusivity: The granted patent provides MERSANA THERAPEUTICS, INC. with a period of market exclusivity in Lithuania for its XMT-1536 ADC. This exclusivity is crucial for recouping R&D investments and establishing a commercial presence without direct competition from generic or biosimilar versions of the patented product.
- Valuation and Investment: A strong patent portfolio, including patents like LT2785706, enhances a company's valuation. It signals to investors the defensibility of its intellectual property and the potential for future revenue streams, making it an attractive prospect for funding R&D activities and commercial expansion.
- Partnership and Licensing Opportunities: The patent can serve as a basis for licensing agreements or strategic partnerships. Companies with complementary technologies or market access in Lithuania may seek to license the rights to XMT-1536, generating revenue for Mersana and facilitating broader access to the therapy.
- Competitive Advantage: The patent secures a competitive edge by preventing other entities from manufacturing, using, or selling the patented XMT-1536 ADC within Lithuania during the patent term.
R&D Significance:
- Platform Protection: Beyond XMT-1536, the underlying technology and understanding of FRα targeting, ADC development, and specific payloads protected by LT2785706 contribute to Mersana's broader ADC platform. This allows for the development of next-generation FRα-targeting ADCs or ADCs targeting other antigens using similar technological principles.
- Foundation for Clinical Development: The patent underpins the ongoing clinical development of XMT-1536. Companies are more likely to invest heavily in clinical trials and regulatory approvals when their core intellectual property is robustly protected.
- Guidance for Future Innovation: While protecting existing inventions, patents also serve as a source of technical information, guiding future R&D efforts. Researchers can learn from the disclosed technology to develop novel approaches that circumvent existing patents or build upon the patented concepts.
- Intellectual Property Strategy: The existence and scope of LT2785706 inform MERSANA THERAPEUTICS, INC.'s overall intellectual property strategy. It helps in identifying white spaces and planning for future patent filings to further strengthen their competitive position in the oncology ADC market.
The commercial and R&D significance of LT2785706 is directly tied to the therapeutic potential of XMT-1536. If XMT-1536 proves to be a safe and effective treatment for FRα-expressing cancers, the patent will be instrumental in enabling MERSANA THERAPEUTICS, INC. to capitalize on this therapeutic advancement in Lithuania.
Key Takeaways
Patent LT2785706 grants MERSANA THERAPEUTICS, INC. protection for the antibody-drug conjugate XMT-1536 and its use in treating FRα-expressing cancers. The patent's claims define specific antibodies targeting FRα, cytotoxic payloads, and linker technologies. In Lithuania, the patent landscape for FRα-targeting ADCs is characterized by Mersana's singular patent for XMT-1536, indicating limited direct competition for this specific compound. However, broader ADC and FRα targeting technologies are subject to more widespread patenting. LT2785706 provides MERSANA THERAPEUTICS, INC. with market exclusivity in Lithuania, enhances its corporate valuation, and supports ongoing clinical development and future R&D initiatives in the oncology ADC space.
Frequently Asked Questions
-
What specific cancers can be treated with the technology described in LT2785706?
The patent claims methods for treating cancers characterized by the overexpression of human folate receptor alpha (FRα). This includes, but is not limited to, ovarian cancer, non-small cell lung cancer, and breast cancer, among other FRα-positive epithelial malignancies.
-
What is the cytotoxic payload used in the antibody-drug conjugate XMT-1536?
The patent specifies that the cytotoxic payload can be a derivative of a hydroxystilbamidine, an auristatin, a maytansinoid, or a duocarmycin. The specific payload within XMT-1536 is designed for high potency.
-
How long will LT2785706 provide market exclusivity in Lithuania?
The duration of patent protection for LT2785706 in Lithuania is typically 20 years from the filing date of the application. However, patent term extensions may be available under specific circumstances, such as for regulatory delays.
-
Does patent LT2785706 prevent the use of other FRα-targeting therapies in Lithuania?
Patent LT2785706 specifically protects the antibody-drug conjugate XMT-1536 and its method of use. It does not broadly prevent the development or use of other FRα-targeting therapies that do not infringe on the patent's claims, such as different ADC constructs, small molecule inhibitors, or immunotherapies.
-
Are there any known direct competitors or similar patented technologies to XMT-1536 in Lithuania?
Based on current analysis, patent LT2785706 appears to be the primary patent protecting the specific XMT-1536 ADC in Lithuania. While the broader field of FRα targeting and ADC technology is active, direct patent filings for competing FRα-targeting ADCs with similar scope and claims in Lithuania are not prominently identified in this analysis.
Citations
[1] MERSANA THERAPEUTICS, INC. (2019). Pharmaceutical composition and method for treating cancer. LT2785706 (Lithuanian Patent Application).
